NBIXNeurocrine Biosciences, Inc.

What Happened

Neurocrine Biosciences, Inc. filed its 10-Q quarterly report with the SEC on November 2, 2026, covering the third quarter of fiscal year 2026. The filing's official XBRL data shows revenue from contracts with customers (excluding assessed tax) of $2.055 billion for Q3 FY2026, alongside net income of $324.9 million and operating income of $408.2 million for the same period. Earnings per share came in at $3.27 basic and $3.19 diluted for the quarter. The scale of these results — over $2 billion in quarterly revenue — marks a substantial operational milestone for the company.

Why It Matters

The Q3 2026 results represent a dramatic illustration of how far Neurocrine has grown: for context, the same filing's XBRL data includes a historical revenue figure of just $6.335 million from Q2 FY2018, underscoring the company's multi-year commercial transformation. For investors, the combination of $408.2 million in operating income against $2.055 billion in revenue implies a healthy operating margin for a commercial-stage biopharma, and diluted EPS of $3.19 for a single quarter indicates the business is generating meaningful per-share earnings power. The stock's reaction — up +15.87% to $168.41 at the time of this report — reflects that the market views these results as materially above expectations.

Analysis

Several elements of this filing stand out:

• Revenue trajectory: A $2.055 billion quarterly revenue figure for a company that generated $6.335 million in a quarter just eight years ago signals an extraordinary commercial ramp, almost certainly anchored by the maturation of Neurocrine's approved product portfolio.
• Profitability quality: Operating income of $408.2 million versus net income of $324.9 million suggests the company is carrying meaningful non-operating costs (interest expense, taxes, or other items) beneath the operating line — but the absolute net income figure is still substantial.
• EPS momentum: Diluted EPS of $3.19 for a single quarter, if sustained or grown, would represent significant annualized earnings power. Investors will want to watch whether this quarter represents a seasonal high or a new run-rate floor.
• Market reaction: A +15.87% single-session move on earnings day is unusually large for a large-cap biopharma and suggests the street was positioned well below actual results, or that forward guidance included with the full 10-Q exceeded consensus expectations.

The key variables to monitor going forward are whether Neurocrine can maintain this revenue level into Q4 FY2026 and full-year FY2027, and how management addresses pipeline investment relative to the growing profit base.

Disclaimer

This report is provided for informational and news purposes only, based solely on data extracted from Neurocrine Biosciences' SEC filing and its official XBRL-tagged financial data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation of any kind. No rating or price target is expressed or implied. Investors should conduct their own due diligence and consult a qualified financial professional before making investment decisions.

Source

Filed with the SEC on 2026-11-02. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/nbix-20260930.htm